MD Anderson research makes ASCO Clinical Cancer Advances for 2012
Two papers published by MD Anderson clinical researchers are included in the American Society of Clinical Oncology's report, Clinical Cancer Advances 2012: ASCO's Annual Report on Progress Against Cancer.
The world's largest oncology organization annually conducts an independent review of advances in clinical cancer research in the past year that have the greatest potential to improve patients' survival and quality of life. The report is compiled under the guidance of 21 experts in specific areas of cancer research.
MD Anderson's publications addressed serous ovarian carcinoma, the most difficult-to-treat version of that cancer, and chronic myeloid leukemia.
Study titles and principal investigators are:
Jorge Cortes, M.D., professor in MD Anderson's Department of Leukemia, "A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation." Presented at the ASCO 2012 annual meeting, data show ponatinib, a third-generation tyrosine kinase inhibitor, acts against disease with specific resistance mutations that other drugs are usually unable to reach.
Yuexin Liu, Ph.D., instructor in MD Anderson's Department of Pathology, "Integrated Analysis of Gene Expression and Tumor Nuclear Image Profiles Associated with Chemotherapy Response in Serous Ovarian Carcinoma." Published in PLOS One in May 2012, this study found a genetic signature that accurately predicts chemotherapy response in serous ovarian cancer.